Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Dosing in Primary Immune Thrombocytopenia
NCT03258866Phase 4Completed
- Sponsor
- Shandong University
- Start
- Jan 2010
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab in primary immune thrombocytopenia (ITP) (2 arms), sponsored by Shandong University. Primary endpoint: Evaluation of platelet response (continuous response rate) at 1 year. Started Jan 2010; status: completed.
02
Drugs
rituximab
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03258866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258866.